Navigation Links
BioCryst to Present at Oppenheimer Healthcare Conference
Date:10/29/2009

BIRMINGHAM, Ala., Oct. 29 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co., Inc. 20th Annual Healthcare Conference in New York on Wednesday, November 4, 2009 at 1:35 p.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at www.biocryst.com.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Limited validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

    BCRXW

    SOURCE BioCryst Pharmaceuticals, Inc.


    '/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Emergency Use Authorization Granted For BioCrysts Peramivir
2. BioCryst to Present at JMP Securities Healthcare Conference
3. BioCryst Clarifies Government Declaration Regarding Peramivir
4. BioCryst Provides Update Regarding Peramivir for Influenza
5. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
6. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
7. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
10. BioCryst Updates Peramivir Clinical Development Plan
11. BioCryst Provides Forodesine HCl Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... 2016 Transparency Market Research has ... Insufficiency Market - Global Industry Analysis, Size, Share, Growth, ... the report, the exocrine pancreatic insufficiency market is anticipated ... to 2023 to reach US$2.85 Bn by 2023. ... by the deficiency of the exocrine pancreatic enzymes, causing ...
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... anticipated, web-based software module. The cutting-edge feature provides end users with an ... Izenda’s self-service business intelligence solution and its analytics engine. , This ...
(Date:5/24/2016)... ... May 24, 2016 , ... Celebration is in the Air, ... its 5th Annual Photo Contest. The label contest is underway, and hundreds of ... include a GoPro Hero4, a 40-inch high-definition flat-screen television, an Apple iPad Air ...
(Date:5/23/2016)... ... 23, 2016 , ... On Sunday, May 15, Rockynol Retirement ... assisted living center. After 18 months of construction, the new state-of-the-art structure was ... provides the latest in assisted living amenities and services, offering six different studio ...
(Date:5/23/2016)... ... ... Edward D. Buckingham, M.D . is excited announce that he has been ... out by the National Consumer Advisory Board to honor excellence in medicine. Only doctors ... award. , The National Consumer Advisory Board (NCAB) is a private organization created to ...
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... surgeons have noted that, less than 1% of United Kingdom residents who could benefit ... UK’s National Health Service (NHS) increases the number of bariatric procedures it offers to ...
Breaking Medicine News(10 mins):